Subcutaneous teicoplanin in staphylococcal bone and joint infections


We aimed to describe the use of subcutaneous teicoplanin as an alternative for the treatment of staphylococcal bone and joint infections.


A retrospective multicentric cohort (2002–2015) was conducted with patients receiving sub-cutaneous teicoplanin for a staphylococcal bone and joint infection.Results. – Forty patients were assessed. A median loading dose of 9.4 mg/kg/12 h (IQR, 6.1–13.1)was administered to 35 patients, subcutaneously for 18 of them. Thirteen of these patients receivedthree injections per week. No excess risk of failure was identified. The trough level was not signifi-cantly different between the various routes (p = 0.462), and was significantly higher if the loading dosewas ≥ 9 mg/kg/injection (p < 10−3).


The use of subcutaneous teicoplanin seems to be acceptable as an alternative to other routesof administration for antibiotics.